Authors

Daniel M Musher

Language

English

Publication Date

9-3-2025

Journal

Antimicrobial Agents and Chemotherapy

DOI

10.1128/aac.00780-25

PMID

40801833

PMCID

PMC12406684

PubMedCentral® Posted Date

8-13-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Although the article by J Càmara, I Grau, A González-Díaz, N Santos, et al. (Antimicrob Agents Chemother 69:e00237-25, 2025, https://doi.org/10.1128/aac.00237-25) suggests that ceftriaxone is greatly superior to amoxicillin in treating pneumonia due to pneumococci with an MIC > 2 mg/L, much of the difference in efficacy of the two drugs may have been due to dosage, route, and times of administration of the amoxicillin.

Keywords

Ceftriaxone, Streptococcus pneumoniae, Amoxicillin, Anti-Bacterial Agents, Humans, Microbial Sensitivity Tests, Pneumonia, Pneumococcal, Streptococcus pneumoniae, amoxicillin, ceftriaxone

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.